ストックスクリーナーアプリを入手
0.00
100.00%
-3.41
前日終値:
$3.41
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$524.82M
収益：
$117.10K
当期純損益:
$-161.61M
株価収益率:
0.00
EPS:
-2.4059
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$6.30
Opthea Limited Adr Stock (OPT) Company Profile
OPT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OPT
Opthea Limited Adr
|
0.00 | 524.82M | 117.10K | -161.61M | 0 | -2.4059 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.46 | 120.29B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
548.35 | 60.26B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
389.20 | 43.10B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
672.73 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
300.38 | 33.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Opthea Limited Adr Stock (OPT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-25 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-03-25 | ダウングレード | Jefferies | Buy → Underperform |
| 2025-03-25 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-03-24 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-12-08 | 開始されました | H.C. Wainwright | Buy |
| 2022-04-26 | 開始されました | SVB Leerink | Outperform |
| 2020-11-17 | 開始されました | Citigroup | Buy |
| 2020-11-11 | 開始されました | Oppenheimer | Outperform |
| 2020-11-11 | 開始されました | SVB Leerink | Outperform |
| 2020-11-11 | 開始されました | Truist | Buy |
すべてを表示
Opthea Limited Adr (OPT) 最新ニュース
Opthea (NASDAQ:OPT) Stock Price Up 7.2% – What’s Next? - Defense World
Opthea Limited Depositary Receipt Stock Analysis and ForecastHigh-octane gains - jammulinksnews.com
Opthea (NASDAQ:OPT) Stock Price Up 7.2% – Time to Buy? - Defense World
Opthea Limited Relocates Registered Office to Melbourne - TipRanks
Millennium Management LLC Reduces Stock Holdings in Opthea Limited (NASDAQ:OPT) - Defense World
Citadel Advisors LLC Takes $79,000 Position in Opthea Limited (NASDAQ:OPT) - Defense World
Opthea Limited (NASDAQ:OPT) Given Average Recommendation of “Hold” by Brokerages - Defense World
Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and ALX Oncology Holdings (ALXO) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), ACADIA Pharmaceuticals (ACAD) and Quanterix (QTRX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Arcellx Inc (ACLX) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Organon (OGN), Diamedica Therapeutics (DMAC) and Nkarta (NKTX) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Relmada Therapeutics (RLMD) and Roivant Sciences (ROIV) - The Globe and Mail
Opthea Limited (NASDAQ:OPT) Given Average Rating of “Hold” by Analysts - Defense World
Sarepta Therapeutics (SRPT) Gets a Buy from Oppenheimer - The Globe and Mail
Analysts Conflicted on These Healthcare Names: Spyre Therapeutics (SYRE), Fresenius Medical Care (FMS) and Jazz Pharmaceuticals (JAZZ) - The Globe and Mail
Brokerages Set Opthea Limited (NASDAQ:OPT) PT at $1.33 - Defense World
Layoff Tracker: Opthea Slashes 65% of Staff, Pfizer Cuts 56 - BioSpace
Opthea Ltd shares corporate update in SEC filing - Investing.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Opthea Announces Termination of ShORe and COAST Trials of Sozinibercept - HCPLive
Opthea Halts Wet AMD Clinical Trials By Investing.com - Investing.com South Africa
Opthea Halts Wet AMD Clinical Trials - Investing.com
Opthea Limited (NASDAQ:OPT) Receives $1.33 Consensus PT from Brokerages - Defense World
Hold Rating Issued for Opthea Limited Amid Uncertainty Following Phase 3 Trial Failure - TipRanks
Opthea Limited: Hold Rating Amid Phase 3 Trial Failure and Financial Uncertainty - TipRanks
Opthea’s COAST Phase 3 Trial Fails to Meet Primary Endpoint, Raising Financial Concerns - TipRanks
Opthea COAST trial misses primary endpoint, enters talks with DFA Investors - TipRanks
Opthea reports phase 3 trial results for eye treatment - Investing.com
Promising Developments and Strong Financial Position Propel AbSci’s Growth Prospects - TipRanks
Opthea Limited Announces New Securities Quotation on ASX - TipRanks
Opthea Limited Reports Increased Losses Amid Clinical Advancements - TipRanks
Optimistic Buy Rating for Opthea Limited Driven by Promising Phase 3 Trials and Innovative AMD Treatment - TipRanks
Opthea reports mid-year financial results - Investing.com
Opthea Ltd completes key drug product campaign - Investing.com
Opthea Completes Key Phase 3 Trial Milestone in Wet AMD Treatment - TipRanks
Opthea Limited completes week 52 patient visits in the COAST trial - Ophthalmology Times
Optimistic Outlook and Buy Rating for Opthea Limited Amid Promising Phase 3 Trials and Strong Financial Position - TipRanks
Opthea to Present at Oppenheimer Healthcare Conference - GlobeNewswire Inc.
OPTOpthea Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Is Opthea Limited (OPT) One of the Best ASX Stocks to Buy According to Hedge Funds? - Insider Monkey
Opthea Unveils Promising Wet AMD Therapy at Investor Day - TipRanks
Why Opthea (OPT) Is Among the Best Australian Stocks to Buy Now? - Yahoo Finance
Opthea Sets Key 2025 Investor Events to Showcase Breakthrough Wet AMD Treatment Sozinibercept - StockTitan
Opthea Limited Reports Earnings Results for the Half Year Ended December 31, 2024 - Marketscreener.com
Opthea to Present Phase 3 Trial Update at J.P. Morgan Healthcare Conference - TipRanks
Race Oncology bolsters leadership - The Australian
Opthea Limited CEO to Present at Citi 2024 Global Healthcare Conference in Miami - Quiver Quantitative
Opthea Limited Targets AMD Market with Sozinibercept - TipRanks
Opthea Appoints Kathy Connell to Board of Directors - The Manila Times
Opthea's Wet AMD Program Featured at Ophthalmology Events - The Manila Times
Opthea to Participate in November Investor Conferences - The Manila Times
Opthea Limited Adr (OPT) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
1.72%
大文字化:
|
ボリューム (24 時間):